Clinical Trials Logo

Clinical Trial Summary

Brief Summary: This is a Phase I, first-in-human, open-label, multi-center study designed to explore the safety, tolerability, PK, and anti-tumor antitumor activity of ANS014004 monotherapy in subjects with locally advanced or metastatic solid tumors. - The study consists of two parts: a dose-escalation part (Part 1) and a dose-expansion part (Part 2). For each subject, the study will consist of a screening period (Day -28 to Day -1), a treatment period (until discontinuation of treatment) and a follow-up period (including safety follow-up and survival follow-up). - During the Treatment Period, subjects will receive ANS014004 single-agent oral administration until the subject meets any treatment termination criteria. 1, The dose-escalation part (Part 1) will consist of a single-dose period and a multiple-dose period (28 days per cycle), participants during dose escalation will receive a single dose of ANS014004 on Day 1 of the single-dose period in order to obtain complete PK parameters for the single dose. There will be a 7-day washout period between the single dosing period and the multiple dosing period at the same dose level. If no dose-limiting toxicity (DLT) occurs during the 7-day washout period, participants will begin Cycle 1 (28 days per cycle) multiple dosing treatment on Day 8, receiving ANS014004 once daily (QD). participants in the backfill cohort will enter the multiple dosing period directly. The specific dose which participant receives will depend on the different cohort assignments. The dose-escalation part (Part 1) will use the initial accelerated titration design (ATD) and the traditional "3 + 3" design to determine the MTD of ANS014004 in subjects with locally advanced or metastatic solid tumors. 2. In the Dose Expansion (Part 2), participants, will receive oral administration of ANS014004 QD at each treatment cycle (28 days per cycle). An end-of-treatment (EOT) visit will be conducted within 7 days of the final dose or investigator decision to discontinue. All subjects will undergo imaging evaluations of their tumors every 8 weeks until disease progression is confirmed by the investigator, the subject begins new antitumor therapy, dies, is lost to follow-up, or withdraws from the study, whichever occurs first.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Locally Advanced or Metastatic Solid Tumors
  • Neoplasms

NCT number NCT06328439
Study type Interventional
Source Avistone Biotechnology Co., Ltd.
Contact Weizhe Xue, Ph.D Weizhe Xue
Phone +86-10-84148931
Email xueweizhe@pearlbio.cn
Status Recruiting
Phase Phase 1
Start date March 19, 2024
Completion date January 31, 2028

See also
  Status Clinical Trial Phase
Terminated NCT04564417 - First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04511845 - A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Active, not recruiting NCT04128423 - Study of AMV564 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05012618 - A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03736850 - Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05137275 - Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors Early Phase 1
Completed NCT01021748 - A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) Phase 1
Completed NCT01713036 - Oral Bioavailability and Mass Balance Trial With Pimasertib Phase 1
Recruiting NCT05116709 - Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05102214 - HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06349811 - A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03478995 - Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06293651 - Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05830539 - IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT05205109 - A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05360381 - HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03150810 - Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05957471 - Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03565991 - Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Phase 2